Date: 2011-11-09
Type of information: Development agreement
Compound: pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb
Company: Dako (Denmark) BMS (USA)
Therapeutic area:
Type agreement: development
Action mechanism:
Disease:
Details: Dako has entered into a broad framework agreement with Bristol-Myers Squibb Company on the development of pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb.The agreement builds on a collaboration begun in 2008.
Financial terms:
Latest news:
